PharmTech Drug Digest 11.20
News|Articles|May 25, 2016

Micro-Macinazione Opens New Storage Facility to Meet Growing Business

The new 500-meter-square warehouse will hold incoming materials, including already micronized highly potent substances and cytotoxic products.

Micro-Macinazione, a provider of micronization services and equipment based in Switzerland, announced that it has established a new warehouse in a move to expand its storage capacity so that it can meet increasing customer demand. Swissmedic, the Swiss agency for therapeutic products and quality standards for GMP, inspected and certified the company’s new warehouse in Molinazzo di Monteggio on May 10.

The 500-meter-square storage facility will house incoming materials, including already micronized highly potent substances and cytotoxic products, which have special safety requirements. The warehouse also has extra space on two floors for 630 Euro-pallets.

Micro-Macinazione noted that sales were up 23.4% in the first quarter of 2016 compared to the same period in 2015. During the past two years, the company invested more than CHF 4 million to establish a new R&D department, build a new control banding system, and construct new production units for the micronization of highly potent substances and cytotoxic products. The company also has a new jet mill for processing large volumes of highly active ingredients.

Source: Micro-Macinazione 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.